| Entry |
|
| Name |
Mutation-caused aberrant Htt to CREB-mediated transcription
|
| Definition |
HTT* -| (CREB+TAF4) => PPARGC1A |
| Expanded |
3064v1 -| ((10488,1385,1386,1388,148327,468,64764,84699,90993,9586)+6874) => 10891 |
| Class |
|
| Type |
Variant
|
| Pathway |
|
| Disease |
|
| Gene |
| 10488 | CREB3; cAMP responsive element binding protein 3 |
| 1385 | CREB1; cAMP responsive element binding protein 1 |
| 1386 | ATF2; activating transcription factor 2 |
| 1388 | ATF6B; activating transcription factor 6 beta |
| 148327 | CREB3L4; cAMP responsive element binding protein 3 like 4 |
| 468 | ATF4; activating transcription factor 4 |
| 64764 | CREB3L2; cAMP responsive element binding protein 3 like 2 |
| 84699 | CREB3L3; cAMP responsive element binding protein 3 like 3 |
| 90993 | CREB3L1; cAMP responsive element binding protein 3 like 1 |
| 9586 | CREB5; cAMP responsive element binding protein 5 |
| 6874 | TAF4; TATA-box binding protein associated factor 4 |
| 10891 | PPARGC1A; PPARG coactivator 1 alpha |
|
| Variant |
|
| Reference |
|
| Authors |
Bossy-Wetzel E, Petrilli A, Knott AB |
| Title |
Mutant huntingtin and mitochondrial dysfunction. |
| Journal |
|
| Reference |
|
| Authors |
McGill JK, Beal MF |
| Title |
PGC-1alpha, a new therapeutic target in Huntington's disease? |
| Journal |
|
| Reference |
|
| Authors |
Paul BD, Snyder SH |
| Title |
Impaired Redox Signaling in Huntington's Disease: Therapeutic Implications. |
| Journal |
|
| Reference |
|
| Authors |
Intihar TA, Martinez EA, Gomez-Pastor R |
| Title |
Mitochondrial Dysfunction in Huntington's Disease; Interplay Between HSF1, p53 and PGC-1alpha Transcription Factors. |
| Journal |
|
| LinkDB |
|